Automotive Wenzh (605088.SS) traded flat 0 % during a 24 hours period ending at 10:07 PM Central Europe on Tuesday 27th. One Automotive Wenzh stock can currently be bought for about CNY 19.54 on popular exchanges. Current supply of Automotive Wenzh stocks is 202.6 mn. Automotive Wenzh has a current market capitalization of CNY 4 bn and approximately CNY 95.9 mn worth of Automotive Wenzh was traded on exchanges in the last 24 hours. Since last month end, Automotive Wenzh has traded -18.13 % down. Simple moving average of last 200 days is at CNY 24.52. The highest price of past 52 weeks was recorded at CNY 43.7 on 02/10/2026. 52 weeks low was at CNY 18.76 on 10/23/2026.
Here is how related stocks have performed in the past 24 hours:
Winall Hi-tech Seed (300087.SZ) traded flat 0 % and now trades at CNY 4.98. Winall Hi-tech Seed has a market capitalisation of CNY 4.8 bn.
Billion Industrial (2299.HK) traded flat 0 % and now trades at HKD 11.13. Billion Industrial has a market capitalisation of HKD 5.7 bn. Current price/earnings ratio for Billion Industrial is 7.98.
Hubei Century Network Tech (300494.SZ) traded flat 0 % and now trades at CNY 9.58. Hubei Century Network Tech has a market capitalisation of CNY 4.8 bn. On Monday, the Shanghai Composite finished slightly higher after a day of mixed activity in the market. The technology sector, particularly the robot‑related segment, remained active, with several companies in the physical‑agent and human‑like‑robot niches posting gains, while the broader hardware and semiconductor groups saw weaker performance. In contrast, the gaming cluster experienced a notable rally, driven by gains in major titles and platform operators, reflecting ongoing momentum in domestic game development and overseas expansion. Consumer‑goods stocks, especially those in the food and beverage area, also posted gains. Overall, the market’s rebound was supported by solid activity in the robot and gaming sectors, despite a general decline in the more hardware‑heavy portions of the index.
Reach Machinery (301596.SZ) traded flat 0 % and now trades at CNY 45.26. Reach Machinery has a market capitalisation of CNY 4.8 bn. Reach Machinery Co. Ltd. reported a notable improvement in its quarterly earnings, signaling a positive shift in its financial trajectory. The company posted a substantial rise in revenue for the third quarter, accompanied by a strong increase in profit attributable to shareholders. This growth outpaced its performance in the preceding quarters, indicating a more robust operational pace. Reach Machinery, recognized as a national high‑technology enterprise and a “small giant” in the specialized industry, focuses on the development, production, and sale of key components for automation equipment, such as electromagnetic brakes and harmonic reducers. Its products serve sectors including robotics, CNC machine tools, and elevators, positioning the firm within the broader industrial automation and intelligent manufacturing landscape. Analysts suggest that ongoing demand for domestic component supply and the expanding market for new‑energy equipment could continue to support the company’s medium‑ to long‑term growth prospects.
Ahwb (301520.SZ) traded flat 0 % and now trades at CNY 48.99. Current market capitalisation for Ahwb is CNY 4.8 bn. Current price/earnings ratio for Ahwb is 583.99. In recent market activity, the AI‑pharma sector has attracted considerable capital flow, with several companies reporting notable gains. Analysts highlight that the sector’s growth is tied to advances in AI‑driven drug discovery, protein synthesis, and high‑throughput experimental validation. Firms positioned as providers of essential wet‑lab services—such as automated protein expression and assay platforms—have seen strong investor interest, reflecting their role in bridging AI predictions to tangible data. Corporate disclosures indicate that while some entities remain in early‑stage losses due to substantial research expenditure, they are building proprietary experimental infrastructure that may underpin future commercial success. Industry observers note that the sector is transitioning from isolated pilot projects toward larger, clinically relevant pipelines, with multiple AI‑derived candidates entering late‑stage trials. The broader trend suggests a gradual shift from concept to validated commercial applications within the AI‑pharma landscape.